Long-Term Follow-Up With Zanubrutinib Across CLL Patient Populations

Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK inhibitor to chemoimmunotherapy in patients with chronic lymphocytic leukemia. He explains how the efficacy benefit and manageable safety profile for zanubrutinib was observed across patient subgroups, including older and younger patients, as well as both high- and low-risk patients. Ermann also expands on the benefit in elderly patients (aged ≥80 years) with highlights from a recent subgroup analysis from SEQUOIA.